Turmeric (pictured) contains the active compound curcumin, which can now be more easily absorbed by the body thanks to nanotechnology.
University of South Australia
Treatment for Alzheimer’s and genital herpes
For years, curry lovers have sworn by the anti-inflammatory properties of turmeric, but its active compound, curcumin, has long frustrated scientists hoping to validate these claims with clinical studies.
The failure of the body to easily absorb curcumin has been a thorn in the side of medical researchers seeking scientific proof that curcumin can successfully treat cancer, heart disease, Alzheimer’s and many other chronic health conditions.
Now, researchers from the University of South Australia (UniSA), McMaster University in Canada and Texas A&M University have shown that curcumin can be delivered effectively into human cells via tiny nanoparticles.
Sanjay Garg, a professor of pharmaceutical science at UniSA, and his colleague Dr Ankit Parikh are part of an international team that has developed a nano formulation which changes curcumin’s behaviour to increase its oral bioavailability by 117 per cent.
The researchers have shown in animal experiments that nanoparticles containing curcumin not only prevents cognitive deterioration but also reverses the damage. This finding paves the way for clinical development trials for Alzheimer’s.
Co-author Professor Xin-Fu Zhou, a UniSA neuroscientist, says the new formulation offers a potential solution for Alzheimer’s disease.
“Curcumin is a compound that suppresses oxidative stress and inflammation, both key pathological factors for Alzheimer’s, and it also helps remove amyloid plaques, small fragments of protein that clump together in the brains of Alzheimer disease patients,” Prof Zhou says.
The same delivery method is now being tested to show that curcumin can also prevent the spread of genital herpes.
“To treat genital herpes (HSV-2) you need a form of curcumin that is better absorbed, which is why it needs to be encapsulated in a nano formulation,” Prof Garg says.
“Curcumin can stop the genital herpes virus, it helps in reducing the inflammation and makes it less susceptible to HIV and other STIs,” Prof Garg says.
Women are biologically more vulnerable to genital herpes as bacterial and viral infections in the female genital tract (FGT) impair the mucosal barrier. Curcumin, however, can minimize genital inflammation and control against HSV-2 infection, which would assist in the prevention of HIV infection in the FGT.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Curcumin Market Size Worth $151.9 Million by 2027 | CAGR: 12.7%: Grand View Research, Inc.on May 5, 2020 at 2:48 am
In Europe, the application of curcumin in the pharmaceuticals sector accounted for a share of 57.2% in terms of revenue in 2019 owing to increasing focus on marketing of capsules/tablets that ...
- Curcumin Market Size Worth $151.9 Million by 2027 | CAGR: 12.7%: Grand View Research, Inc.on May 5, 2020 at 2:00 am
Read 120 page research report with ToC on "Curcumin Market Size, Share & Trends Analysis Report By Application (Pharmaceutical, Food, Cosmetics), By Region (North America, Europe, Asia Pacific ...
- Curcumin Market Size Worth $151.9 Million by 2027 | CAGR: 12.7%: Grand View Research, Inc.on May 5, 2020 at 1:44 am
SAN FRANCISCO, May 5, 2020 /PRNewswire/ -- The global curcumin market size is expected to reach USD 151.9 million by 2027, expanding at a CAGR of 12.7%, according to a new report by Grand View ...
- Curcumin Market Size Worth $151.9 Million by 2027 | CAGR: 12.7%: Grand View Research, Inc.on May 5, 2020 at 1:35 am
The global curcumin market size is expected to reach USD 151.9 million by 2027, expanding at a CAGR of 12.7%, according to a new report ...
- Could This Spice Be Your Next Performance Booster?on April 29, 2020 at 8:21 am
While more research will yield additional answers, this might be a cue to add a bit more spice into your life—or at least consider a post-ride curry dish. “These studies showed significant results in ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- New drug trial looks at remdesivir combined with anti-inflammatoryon May 8, 2020 at 12:32 pm
Miller The National Institute of Allergy and Infectious Disease has begun a trial looking at the effects of remdesivir combined with a second drug, called baricitinib, on treating COVID-19.
- NIH begins study of remdesivir with anti-inflammatory drug to treat COVID-19on May 8, 2020 at 12:20 pm
The trial is currently enrolling adults hospitalized with COVID-19 in the United States and is expected to study the treatment combination in more than 1,000 participants. Interest in remdesivir has ...
- BRIEF-NIH Clinical Trial Testing Antiviral Remdesivir Plus Anti-Inflammatory Drug Baricitinib For COVID-19 Beginson May 8, 2020 at 11:32 am
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES: * NIH CLINICAL TRIAL TESTING ANTIVIRAL REMDESIVIR PLUS ANTI-INFLAMMATORY DRUG BARICITINIB FOR COVID-19 BEG ...
- NIH clinical trial tests Remdesivir plus anti-inflammatory drug Baricitinib for COVID-19on May 8, 2020 at 11:24 am
A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for COVID-19 ...
- NIH clinical trial testing antiviral remdesivir plus anti-inflammatory drug baricitinib for COVID-19 beginson May 8, 2020 at 11:21 am
A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for ...